Pages that link to "Q39998537"

The following pages link to Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL. (Q39998537):

Displaying 24 items.

• The Philadelphia chromosome in leukemogenesis (Q26745531) (← links)
• Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers (Q26766271) (← links)
• Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (Q27025242) (← links)
• The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines (Q33409151) (← links)
• Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment. (Q33513975) (← links)
• Translocation Biosensors - Cellular System Integrators to Dissect CRM1-Dependent Nuclear Export by Chemicogenomics (Q34162154) (← links)
• The nuclear translocation assay for intracellular protein-protein interactions and its application to the Bcr coiled-coil domain (Q34171529) (← links)
• Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I (Q34416737) (← links)
• Disruption of Bcr-Abl Coiled Coil Oligomerization by Design (Q35145034) (← links)
• A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia (Q36210636) (← links)
• Structure, regulation, signaling, and targeting of abl kinases in cancer (Q36443429) (← links)
• BCR: a new target in resistance mediated by BCR/ABL-315I? (Q38710583) (← links)
• T-cell receptor transfer into human T cells with ecotropic retroviral vectors. (Q39008906) (← links)
• Cell-penetrating fusion peptides OD1 and OD2 interact with Bcr-Abl and influence the growth and apoptosis of K562 cells (Q39087712) (← links)
• Oleylamine-carbonyl-valinol inhibits auto-phosphorylation activity of native and T315I mutated Bcr-Abl, and exhibits selectivity towards oncogenic Bcr-Abl in SupB15 ALL cell lines (Q39232212) (← links)
• TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization (Q39316870) (← links)
• p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia. (Q39447127) (← links)
• Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL. (Q39792508) (← links)
• The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL. (Q39860473) (← links)
• Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis (Q41948387) (← links)
• SOCS1 function in BCR-ABL mediated myeloproliferative disease is dependent on the cytokine environment (Q42339101) (← links)
• Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding (Q82620304) (← links)
• The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation (Q85003121) (← links)
• Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers (Q92002611) (← links)